Skip to main content

Advertisement

SpringerLink
Log in

Emerging Therapies in Metastatic Prostate Cancer

  • Genitourinary Cancers (DP Petrylak and JW Kim, Section Editors)
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

In the last decade, there have been multiple landmark therapeutic advances for the treatment of metastatic prostate cancer, both in the castration-resistant and hormone-sensitive setting. In this review, we highlight recent progress and ongoing trials for metastatic prostate cancer, including advances in chemotherapy, androgen receptor-directed therapy, targeted therapies, and immunotherapy.

Recent Findings

Several landmark studies for men with metastatic hormone-sensitive prostate cancer demonstrated improvement in overall survival with the addition of docetaxel chemotherapy or abiraterone acetate to standard androgen deprivation therapy. A single-arm phase 2 study of the PARP inhibitor olaparib demonstrated high response rates and more favorable progression-free and overall survival for men with metastatic castration-resistant prostate cancer and DNA repair defects treated with olaparib compared with men without DNA repair defects. Multiple ongoing clinical trials are investigating novel hormonal therapies and combinations of chemotherapy, targeted small molecules, immunotherapy, and radiopharmaceuticals.

Summary

Progress continues to be made in the treatment of metastatic prostate cancer, and ongoing clinical trials continue to investigate novel agents and approaches to treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Howlader N NA, Krapcho M, Miller D, Bishop K, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). . Prostate Cancer SEER Cancer Statistics Review, 1975-2014. 2017.

  2. • Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate Cancer. N Engl J Med. 2015;373(8):737–46. https://doi.org/10.1056/NEJMoa1503747. This trial showed that the addition of six cycles of docetaxel to androgen deprivation therapy in newly diagnosed metastatic hormone-sensitive prostate cancer significantly increased overall survival.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M et al. Long term efficacy and QOL data of chemohormonal therapy (C-HT) in low and high volume hormone naïve metastatic prostate cancer (PrCa): E3805 CHAARTED trial Ann Oncol 2016;27(Supplemental 6).

  4. • James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024):1163–77. https://doi.org/10.1016/S0140-6736(15)01037-5. This trial showed that the addition of six cycles of docetaxel to androgen deprivation therapy in newly diagnosed metastatic hormone-sensitive prostate cancer significantly increased overall survival.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377(4):338–51. https://doi.org/10.1056/NEJMoa1702900.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. • Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377(4):352–60. https://doi.org/10.1056/NEJMoa1704174. This trial showed that the addition of abiraterone and prednisone to androgen deprivation therapy in newly diagnosed metastatic hormone-sensitive prostate cancer significantly increased overall survival.

    Article  CAS  PubMed  Google Scholar 

  7. Saad F, Fizazi K, Jinga V, Efstathiou E, Fong PC, Hart LL, et al. Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial. Lancet Oncol. 2015;16(3):338–48. https://doi.org/10.1016/S1470-2045(15)70027-6.

    Article  CAS  PubMed  Google Scholar 

  8. Fizazi K, Jones R, Oudard S, Efstathiou E, Saad F, de Wit R, et al. Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5. J Clin Oncol. 2015;33(7):723–31. https://doi.org/10.1200/JCO.2014.56.5119.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Tombal B, Borre M, Rathenborg P, Werbrouck P, Van Poppel H, Heidenreich A, et al. Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study. Lancet Oncol. 2014;15(6):592–600. https://doi.org/10.1016/S1470-2045(14)70129-9.

    Article  CAS  PubMed  Google Scholar 

  10. Tombal B, Borre M, Rathenborg P, Werbrouck P, Van Poppel H, Heidenreich A, et al. Long-term anti-tumor activity and safety of enzalutamide monotherapy in hormone-naive prostate cancer: 3-year, open-label, follow-up results. J Urol. 2017;199:459–64. https://doi.org/10.1016/j.juro.2017.08.103.

    Article  PubMed  Google Scholar 

  11. McKay RR, Zurita AJ, Werner L, Bruce JY, Carducci MA, Stein MN, et al. A randomized phase II trial of short-course androgen deprivation therapy with or without bevacizumab for patients with recurrent prostate cancer after definitive local therapy. J Clin Oncol. 2016;34(16):1913–20. https://doi.org/10.1200/JCO.2015.65.3154.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Kelly WK, Halabi S, Carducci M, George D, Mahoney JF, Stadler WM, et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol. 2012;30(13):1534–40. https://doi.org/10.1200/JCO.2011.39.4767.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Pan Q, Sathe A, Black PC, Goebell PJ, Kamat AM, Schmitz-Draeger B, et al. CDK4/6 inhibitors in cancer therapy: a novel treatement strategy for bladder Cancer. Bladder Cancer. 2017;3(2):79–88. https://doi.org/10.3233/BLC-170105.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Chi K AM, Sunderland K, et al. A randomized phase II cross-over study of abiraterone + prednisone (ABI) vs enzalutamide (ENZ) for patients (pts) with metastatic, castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 2017;35:abstract 5002.

  15. Fizazi K, Massard C, Bono P, Jones R, Kataja V, James N, et al. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. Lancet Oncol. 2014;15(9):975–85. https://doi.org/10.1016/S1470-2045(14)70240-2.

    Article  CAS  PubMed  Google Scholar 

  16. Toren PJ, Kim S, Pham S, Mangalji A, Adomat H, Guns ES, et al. Anticancer activity of a novel selective CYP17A1 inhibitor in preclinical models of castrate-resistant prostate cancer. Mol Cancer Ther. 2015;14(1):59–69. https://doi.org/10.1158/1535-7163.MCT-14-0521.

    Article  CAS  PubMed  Google Scholar 

  17. Schweizer MT, Antonarakis ES, Wang H, Ajiboye AS, Spitz A, Cao H, et al. Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study. Sci Transl Med. 2015;7(269):269ra2. https://doi.org/10.1126/scitranslmed.3010563.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med. 2016;375(5):443–53. https://doi.org/10.1056/NEJMoa1603144.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161(5):1215–28. https://doi.org/10.1016/j.cell.2015.05.001.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med. 2015;373(18):1697–708. https://doi.org/10.1056/NEJMoa1506859.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Hussain M, Daignault S, Twardowski P, et al. Abiraterone + prednisone +/- veliparib for patients with metastatic castration-resistant prostate cancer: NCI 9012 updated clinical genomics data. American Society of Clinical Oncology annual meeting (abstract 5001). 2017.

  22. Bono JSD, Hussain M, Thiery-Vuillemin A, Mateo J, Sartor AO, Chi KN et al. PROfound: a randomized phase III trial evaluating olaparib in patients with metastatic castration-resistant prostate cancer and a deleterious homologous recombination DNA repair aberration. Journal of Clinical Oncology. 2017;35(15_suppl):TPS5091-TPS. doi:https://doi.org/10.1200/JCO.2017.35.15_suppl.TPS5091.

  23. Ross RW, Beer TM, Jacobus S, Bubley GJ, Taplin ME, Ryan CW, et al. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. Cancer. 2008;112(3):521–6. https://doi.org/10.1002/cncr.23195.

    Article  CAS  PubMed  Google Scholar 

  24. Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, et al. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res. 2013;19(13):3621–30. https://doi.org/10.1158/1078-0432.CCR-12-3791.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007;7(8):573–84. https://doi.org/10.1038/nrc2167.

    Article  CAS  PubMed  Google Scholar 

  26. Kennedy RD, D’Andrea AD. DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes. J Clin Oncol. 2006;24(23):3799–808. https://doi.org/10.1200/JCO.2005.05.4171.

    Article  CAS  PubMed  Google Scholar 

  27. Corn PG, et al. A multi-institutional randomized phase II study (NCT01505868) of cabazitaxel (CAB) plus or minus carboplatin (CARB) in men with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2015;33(suppl; abstr 5010):2015.

    Google Scholar 

  28. Smith M, De Bono J, Sternberg C, Le Moulec S, Oudard S, De Giorgi U, et al. Phase III study of cabozantinib in previously treated metastatic castration-resistant prostate cancer: COMET-1. J Clin Oncol. 2016;34(25):3005–13. https://doi.org/10.1200/JCO.2015.65.5597.

    Article  CAS  PubMed  Google Scholar 

  29. De Bono J, De Giorgi U, Massard C, et al. Randomized phase II study of AKT blockade with ipatasertib (GDC-0068) and abiraterone (Abi) vs. abi alone in patients with metastatic castration-resistant prostate cancer (mCRPC) after docetaxel chemotherapy (A. MARTIN Study). Journal of Clinical Oncology. 2016;34 supplemental(Abstract 5017).

  30. Graff JN, Alumkal JJ, Drake CG, Thomas GV, Redmond WL, Farhad M, et al. Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer. Oncotarget. 2016;7(33):52810–7. https://doi.org/10.18632/oncotarget.10547.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15(7):700–12. https://doi.org/10.1016/S1470-2045(14)70189-5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Beer TM, Kwon ED, Drake CG, Fizazi K, Logothetis C, Gravis G, et al. Randomized, double-blind, phase III trial of Ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J Clin Oncol. 2017;35(1):40–7. https://doi.org/10.1200/JCO.2016.69.1584.

    Article  CAS  PubMed  Google Scholar 

  33. Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010;28(7):1099–105. https://doi.org/10.1200/JCO.2009.25.0597.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Jha GG, Gupta S, Tagawa ST, Koopmeiners JS, Vivek S, Dudek AZ, et al. A phase II randomized, double-blind study of sipuleucel-T followed by IDO pathway inhibitor, indoximod, or placebo in the treatment of patients with metastatic castration resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 2017;35(15_suppl):3066. https://doi.org/10.1200/JCO.2017.35.15_suppl.3066.

    Google Scholar 

  35. Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fossa SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213–23. https://doi.org/10.1056/NEJMoa1213755.

    Article  CAS  PubMed  Google Scholar 

  36. Tagawa ST, Milowsky MI, Morris M, Vallabhajosula S, Christos P, Akhtar NH, et al. Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013;19(18):5182–91. https://doi.org/10.1158/1078-0432.CCR-13-0231.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Northwestern University Feinberg School of Medicine, Division of Hematology/Oncology and Robert H. Lurie Comprehensive Cancer Center, 676 N. St. Clair St., Chicago, IL, 60611, USA

    Daniel W. Sonnenburg & Alicia K. Morgans

Authors
  1. Daniel W. Sonnenburg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alicia K. Morgans
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Conflict of Interest

Daniel Sonnenburg declares that he has no conflict of interest.

Alicia Morgans has received compensation from Genentech, Bayer, and AztraZeneca for participation on advisory boards, and has received compensation from Janssen for service as a consultant.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Genitourinary Cancers

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sonnenburg, D.W., Morgans, A.K. Emerging Therapies in Metastatic Prostate Cancer. Curr Oncol Rep 20, 46 (2018). https://doi.org/10.1007/s11912-018-0692-z

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11912-018-0692-z

Keywords

Search

Navigation